Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients
OBJECTIVES: The authors have previously tried to develop a model for the testing of novel drug candidates for migraine, using the headache and migraine provoking agent cilostazol. Previous studies have used sumatriptan tablets as the validating drug, but they were not sufficiently effective. In this study we test the effect of subcutaneous sumatriptan on cilostazol induced headache in patients with migraine without aura.
METHOD: Thirty patients with migraine without aura received 200 mg cilostazol on two different study days. The induced headache was treated with subcutaneous sumatriptan in a randomized, double-blind cross-over design. The patients filled out a self-reported headache questionnaire until 12 h after cilostazol.
RESULTS: All 30 patients experienced headache (range 3-10) on both study days and the headache fulfilled the criteria for a migraine-like attack in 73% on the sumatriptan day and in 77% on the placebo day. Sumatriptan injection reduced the headache score 2 h after treatment (p = 0.003). The difference between headache intensity on the sumatriptan day and the placebo day was significant at both 2 h (p = 0.01) and 4 h (p = 0.0007) after treatment.
CONCLUSION: Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients. The cilostazol model may be useful as a tool to test the potential of new anti-migraine drugs.Trial registration: The study is registered on clinicaltrials.gov (NCT03422796).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Cephalalgia : an international journal of headache - 40(2020), 8 vom: 13. Juli, Seite 842-850 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Falkenberg, Katrine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8R78F6L9VO |
|---|
| Anmerkungen: |
Date Completed 26.08.2021 Date Revised 26.08.2021 published: Print-Electronic ClinicalTrials.gov: NCT03422796 Citation Status MEDLINE |
|---|
| doi: |
10.1177/0333102420915166 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308022998 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308022998 | ||
| 003 | DE-627 | ||
| 005 | 20231225130839.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/0333102420915166 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1026.xml |
| 035 | |a (DE-627)NLM308022998 | ||
| 035 | |a (NLM)32216457 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Falkenberg, Katrine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.08.2021 | ||
| 500 | |a Date Revised 26.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03422796 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: The authors have previously tried to develop a model for the testing of novel drug candidates for migraine, using the headache and migraine provoking agent cilostazol. Previous studies have used sumatriptan tablets as the validating drug, but they were not sufficiently effective. In this study we test the effect of subcutaneous sumatriptan on cilostazol induced headache in patients with migraine without aura | ||
| 520 | |a METHOD: Thirty patients with migraine without aura received 200 mg cilostazol on two different study days. The induced headache was treated with subcutaneous sumatriptan in a randomized, double-blind cross-over design. The patients filled out a self-reported headache questionnaire until 12 h after cilostazol | ||
| 520 | |a RESULTS: All 30 patients experienced headache (range 3-10) on both study days and the headache fulfilled the criteria for a migraine-like attack in 73% on the sumatriptan day and in 77% on the placebo day. Sumatriptan injection reduced the headache score 2 h after treatment (p = 0.003). The difference between headache intensity on the sumatriptan day and the placebo day was significant at both 2 h (p = 0.01) and 4 h (p = 0.0007) after treatment | ||
| 520 | |a CONCLUSION: Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients. The cilostazol model may be useful as a tool to test the potential of new anti-migraine drugs.Trial registration: The study is registered on clinicaltrials.gov (NCT03422796) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Migraine | |
| 650 | 4 | |a human model | |
| 650 | 4 | |a migraine treatment | |
| 650 | 7 | |a Serotonin 5-HT1 Receptor Agonists |2 NLM | |
| 650 | 7 | |a Vasodilator Agents |2 NLM | |
| 650 | 7 | |a Sumatriptan |2 NLM | |
| 650 | 7 | |a 8R78F6L9VO |2 NLM | |
| 650 | 7 | |a Cilostazol |2 NLM | |
| 650 | 7 | |a N7Z035406B |2 NLM | |
| 700 | 1 | |a Bjerg, Helene Rønde |e verfasserin |4 aut | |
| 700 | 1 | |a Olesen, Jes |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cephalalgia : an international journal of headache |d 1981 |g 40(2020), 8 vom: 13. Juli, Seite 842-850 |w (DE-627)NLM012712523 |x 1468-2982 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2020 |g number:8 |g day:13 |g month:07 |g pages:842-850 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/0333102420915166 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2020 |e 8 |b 13 |c 07 |h 842-850 | ||